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Background: Accumulating evidence indicates that in utero exposure to arsenic is associated with congenital
defects and long-term disease consequences including cancers. Recent studies suggest that arsenic carcinogenesis
results from epigenetic changes, particularly in DNA methylation. This study aimed to investigate DNA methylation
changes as a result of arsenic exposure in utero and in vitro.
Methods: For the exposure in utero study, a total of seventy-one newborns (fifty-five arsenic-exposed and sixteen
unexposed newborns) were recruited. Arsenic concentrations in the drinking water were measured, and exposure in
newborns was assessed by measurement of arsenic concentrations in cord blood, nails and hair by Inductively
Coupled Plasma Mass Spectrometry (ICP-MS). In the in vitro study, human lymphoblasts were treated with arsenite
at 0-100 μM for two, four and eight hours (short-term) and at 0, 0.5 and 1.0 μM for eight-weeks period (long-term).
DNA methylation was analyzed in cord blood lymphocytes and lymphoblasts treated with arsenite in vitro. Global
DNA methylation was determined as LINE-1 methylation using combined bisulfite restriction analysis (COBRA) and
total 5-methyldeoxycytidine (5MedC) content which was determined by HPLC-MS/MS. Methylation of p53 was
determined at the promoter region using methylation-specific restriction endonuclease digestion with MspI and
HpaII.
Results: Results showed that arsenic-exposed newborns had significantly higher levels of arsenic in cord blood,
fingernails, toenails and hair than those of the unexposed subjects and a slight increase in promoter methylation of
p53 in cord blood lymphocytes which significantly correlated with arsenic accumulation in nails (p< 0.05) was
observed, while LINE-1 methylation was unchanged. Short-term in vitro arsenite treatment in lymphoblastoid cells
clearly demonstrated a significant global hypomethylation, determined as reduction in LINE-1 methylation and total
5-MedC content, and p53 hypermethylation (p< 0.05). However, a slight LINE-1 hypomethylation and transient p53
promoter hypermethylation were observed following long-term in vitro treatment.
Conclusions: This study provides an important finding that in utero arsenic exposure affects DNA methylation,
particularly at the p53 promoter region, which may be linked to the mechanism of arsenic carcinogenesis and the
observed increased incidence of cancer later in life.
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Exposure to arsenic is a major health concern worldwide.
Arsenic is an environmental pollutant that has been classi-
fied as a human carcinogen by the International Agency
for Research on Cancer [1] and the US Environmental
Protection Agency [2]. Epidemiological studies have shown
that chronic exposure to arsenic in drinking water is asso-
ciated with increased risk of various diseases, including
cancers [3]. A number of studies have reported that pos-
sible mechanisms of arsenic carcinogenesis include both
genotoxic and non-genotoxic mechanisms [4]. Genotoxic
effects of arsenic involve chromosome aberrations at toxic
concentrations and aneuploidy as well as delayed mutagen-
esis at non-toxic concentrations [5]. Among genotoxic
effects of arsenic in humans, chromosome aberrations and
micronuclei in different cell types have been found to be
significantly increased [6]. However, a growing body of
evidence suggests that arsenic exerts its carcinogenicity
through epigenetic mechanisms by affecting multiple
cellular pathways, including expression of growth fac-
tors, suppression of cell cycle check points, promotion
of and resistance to apoptosis, inhibition of DNA repair,
and alterations in DNA methylation [7,8].
Epigenetic dysregulation of gene expression as a result of
DNA methylation changes plays an important role in cancer
etiology [9,10]. Global hypomethylation and aberrant pro-
moter methylation of tumor suppressor genes are frequently
found in cancer tissues [11,12]. The epigenetic effects of ar-
senic have been extensively studied, particularly on DNA
methylation alterations. Changes in gene methylation status
mediated by arsenic have been proposed to activate onco-
gene expression or silence tumor suppressor genes, leading
to long-term changes in the activity of genes controlling
cell transformation. Arsenic exposure has been reported to
cause a significant reduction in global DNA methylation
associated with malignant transformation in rat liver epithe-
lial cells [13] and to induce hypermethylation within the
promoter region of the tumor suppressor p53 gene in
human lung adenocarcinoma A549 cells [14]. In addition,
Chanda et al [15] reported that chronic arsenic exposure is
associated with the promoter hypermethylation of p53 and
p16 in lung adenoma in arsenic-exposed residents who were
chronically exposed to arsenic-contaminated drinking water.
Recently, it has been reported that arsenic pollution from
coal-burning caused p53 promoter hypermethylation in one
hundred and twelve Chinese patients with arsenism [16].
The hypermethylation of p53 at the promoter region was
related with the mutation of the p53 gene (exon 5), and
hypomethylation of p53 at exon 5 was also related with its
mutation. The data implicated that arsenic affects both
DNA methylation and mutation of p53. The tumor sup-
pressor gene, p53, is a key factor in DNA damage-signalling
pathways, and p53 hypomethylation is associated with DNA
strand breaks and chromosome instability [17].Arsenic contamination affects millions of people who
are exposed to drinking water at arsenic levels that exceed
the World Health Organization (WHO) safety standard of
10 μg/L. Among arsenic-exposed populations, children are
considered to be a vulnerable group to arsenic exposure.
Epidemiological evidence links in utero and early-life human
exposures to arsenic with increased risk of cancer mortality
during early adulthood [18-20], as well as with develop-
mental and long-term health consequences, including pul-
monary and cardiovasuclar diseases, fetal loss and birth
defects [21]. In an experimental animal study, in utero ex-
posure to inorganic arsenic resulted in a variety of tumors
in the off-spring when they reached adulthood [22-24].
Additionally, it has been proposed that gestational disrup-
tion of normal epigenetic programming by arsenic may
lead to aberrant gene expression, which in turn influences
fetal development and disease risk later in life [25].
In Thailand, one of the areas heavily contaminated with
arsenic is Ron Pibul District of Nakhon Sri Thammarat
Province. This area was the site of tin mining activities for
almost a century. Although most of the mines ceased oper-
ation in the late 1980s, the release of arsenopyrite (FeAsS)
from the tin ore caused extensive arsenic contamination in
many areas of Ron Pibul District. Human health problems
associated with arsenic toxicity in Ron Pibul District were
first recognized in 1987, with the risk of arsenic poisoning
in the population due to drinking and using contaminated
water daily. Reported levels of arsenic in these areas range
from <0.26 to 1000 μg/L [26,27]. Recently, we reported for
the first time that prenatal arsenic exposure in a human
population living in this district, resulted in alarming gene
expression changes in the newborns of exposed mothers.
Altered expression of these arsenic-associated genes shows
a striking dose response relationship to prenatal arsenic
exposure, and a biological network analysis showed that
the arsenic-associated transcripts could modulate numer-
ous biological pathways, including apoptosis, cell signaling,
inflammation and stress response, and ultimately affect
health status [28].
Further to the aforementioned studies on gene expres-
sion, the present study was conducted in the cord blood
samples from the same studied groups to examine the
effects of arsenic exposure in utero on DNA methylation,
focusing on global DNA methylation and p53 promoter
methylation in cord blood lymphocytes of newborn babies.
In parallel with the in utero exposure study, in vitro studies
using a human lymphoblast cell line exposed to arsenic
were also carried out.
Methods
Study locations and subjects
The study was conducted in arsenic contaminated areas in
the Ron Pibul District, Nakhon Sri Thammarat Province,
which is located in the southern peninsula of Thailand.
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hundred square kilometers and has been the site of tin
mining activities for almost a century. Although most of
the mines ceased operation in the late 1980s, the release of
arsenopyrite (FeAsS) from the tin ore has resulted in ar-
senic contamination in many areas. Five villages in the
Ron Pibul District were selected for this study as they had
been classified as high-level arsenic contaminated areas
and arsenicosis. Arsenicosis has not been reported in
central part of Thailand, where arsenic concentrations
in water and soil have been determined to be very low
[29]. Thus, unexposed subjects were selected from those
living in the unexposed area and came to a hospital in
Bangkok for delivery. Arsenic levels in fingernails of
pregnant women confirmed exposed and unexposed
status.
A total of seventy-one newborns, consisting of fifty-five
newborns from mothers living in the Ron Pibul District
and sixteen newborns from unexposed mothers, were
the subjects in this study. All mothers of the newborns
in this study were healthy, non-smokers, had no compli-
cations during pregnancy and underwent vaginal child-
birth without birth stimulation or anesthesia. The mothers
from both groups were age, educational level, and socioe-
conomically matched. Questionnaires were administered
to all participants to obtain personal information regarding
residential history, health history and potential confound-
ing factors, birth and pregnancy information (number of
births, abortions or complications), use of community
drinking water and well water, as well as water and food
consumption habits. Maternal urinary cotinine level was
checked consequently and showed to be in the range of
0-0.43 μg/mmol creatinine, lower than reference back-
ground level of 28 μg/mmol creatinine [30]. Cord blood
samples were collected from January 2004 to December
2005 in the Ron Pibul Hospital (Ron Pibul District) and
the Rajvithi Hospital (Bangkok). This study was conducted
according to the recommendations of the Declaration of
Helsinki (World Medical Association 1989) for inter-
national health research. All pregnant mothers gave writ-
ten informed consent to participate in this study.
Measurement of arsenic concentration in water samples
Water samples were collected in 500 mL plastic bottles
and HNO3 was added to the water samples, which were
stored at 5 °C until analysis. The collected samples were
filtered through 0.45 μm filter membranes prior to analysis
of the dissolved arsenic concentration using ICP-MS.
ICP-MS analysis of arsenic concentration
Arsenic concentrations in the samples were analyzed using
an Octopole ICP-MS. The sample introduction system for
ICP MS consists of a Babington-type nebulizer and spray
chamber cooled by a Peltier system. Arsenic was monitoredat m/z=75, the mass of the only arsenic isotope. Instru-
mentation parameters were Rf power = 1500 W, Carrier
gas =Ar, flow rate = 0.8 L/minute, makeup gas = 0.29 L/
minute, nebulizer pump= 0.1 rps, measurement mode =
peak area of 75As, Integration time = 0.1 second, and
point per peak = 1.
Analysis of arsenic concentration in cord blood
Analysis of arsenic concentrations in cord blood was car-
ried out according to a previously reported procedure,
with modification [31]. Cord blood samples were drawn
from the cubical vein into sterilized tubes containing
heparin (2 units /mL). The cord blood samples were
stored at -70 oC until analysis. A 300 μL aliquot of blood
was digested with 1 mL suprapure nitric acid using a
microwave oven (Milestone ETHOS) with a constant power
(900 watts) and programmable temperature at 110 oC,
180 oC and 200 oC for 3, 7 and 5 minutes, respectively.
The digested samples were analyzed for total arsenic
concentrations by ICP-MS, with the analysis parameters
as previously described.
Analysis of arsenic accumulation in hair and nails
Analysis of arsenic accumulation in hair and nails was
carried out according to a previously reported procedure,
with modification [32,33]. Fingernails and toenails were
clipped and hair samples were cut. The samples were kept
in a zip-lock bag at room temperature until analysis. The
samples both nails and hair (20-30 mg) were transferred to
a polyethylene vial and sequentially washed by adding
2 mL acetone and sonicating in an ultrasonic bath for
twenty minutes, followed by sonicating the samples with
1 % Triton X-100 for twenty minutes, then washing five
times with deionized water and dried. This washing pro-
cedure removes all external contamination without
extracting metals from the nails. The samples were dried
and mixed with 1 mL concentrated HNO3. Subsequently,
samples were microwave digested until the solution was
clear. The digested samples were diluted to 5 mL with
ultrapure water and subjected to ICP-MS analysis of ar-
senic concentration as previously described.
Isolation of cord blood lymphocytes
Human cord blood was collected in 50 mL tubes contain-
ing heparin and kept on ice before lymphocyte separation.
The lymphocytes were isolated by buoyant density using
Ficoll-Paque plus (Amersham). Blood sample was mixed
with one volume of RPMI 1640 medium and carefully
layered in a 50 mL centrifuge tube containing 12 mL
Ficoll-Paque. After centrifugation at 2500 rpm for thirty
minutes at 18-20 °C, the upper layer was removed and
the interface layer collected into a new tube, washed
with two volumes of PBS and centrifuged at 1200 rpm
for ten minutes at 18-20 °C. The supernatant was then
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with PBS. The number of lymphocytes was determined
using a hemacytometer. The lymphocytes were stored at
5 x 106 cells /mL in cold freezing medium. Cell suspen-
sion (2 mL) was transferred to a cryovial, submerged in
a cryo-freezing container and immediately placed in a
-80 °C freezer until analysis.
Cell culture and NaAsO2 treatment
A lymphoblast cell line (RPMI1788), established from
human peripheral blood lymphocytes (profile# TKG0464),
was obtained from the ATCC (#CCL-156). Cord blood
lymphocytes were obtained from participating subjects
(newborns). All cells were cultured in RPMI1640 medium
containing 20 % FBS at 37 °C, 5 % CO2, free from antibio-
tics for twenty-four hours prior to treatment.
The inorganic trivalent arsenic compound (NaAsO2)
was dissolved in the culture medium immediately prior
to use. 1 M of NaAsO2 solution was diluted in order to
make the final concentration in cell culture medium; 0,
10, 20, 50 and 100 μM for the short-term experiment,
and 0.0, 0.5, 1.0 μM for the long-term experiment. There
was duplication of samples at each concentration. Cells
were incubated at 37 °C, 5 % CO2 for twenty-four hours
prior to analysis.
Determination of DNA methylation
DNA isolation
DNA was isolated from cord blood lymphocytes or lympho-
blasts using DNeasy® blood & tissue kits (Qiagen). A frac-
tion of 5 x 106 cells was centrifuged and resuspended in 200
μL PBS. 20 μL protienase K and 4 μL RNase A (100 mg/
mL) were added and incubated for two minutes at room
temperature, lysed in 200 μL buffer AL and incubated at 56 °C
for ten minutes. Ethanol (200 μL) was added, mixed and trans-
ferred to a DNeasy mini spin column, which was then centri-
fuged at 8,000 rpm for one minute. The column was
sequentially washed with AW1 and AW2 buffer. The bound
DNA was eluted with 80 μL buffer AE, incubated at room
temperature for one minute and centrifuged at
8,000 rpm for one minute. The purity and concentration
of total DNA were determined by the ratio of absorbance
at 260/280 and 260/230 nm using a Nanodrop ND-1000.
Analysis of global LINE-1 methylation using combined
bisulfite restriction analysis (COBRA)
Analysis of global LINE-1 methylation using com-
bined bisulfite restriction analysis (COBRA) was car-
ried out according to previously reported method,
with modification [34]. DNA was isolated using a
Qiagen DNA isolation kit, then COBRA using the
bisulfite conversion kit (Qiagen) was performed. This
method is widely used and accepted in DNA methy-
lation studies in a variety of tissues [35-37]. Afraction of DNA (2 μg) was treated with bisulfite
using a EpiTect® Bisulfite kit (Qiagen), which converted
all cytosines to uracils, except methylated cytosines. The
bisulfite DNA conversion was performed using a thermal
cycler according to instructions in the EpiTect® Bisulfite
kit manual. The bisulfite product was amplified with the
specific long interspersed nucleotide elements (LINE-1 re-
petitive element (413 bp)), a surrogate marker of global
DNA methylation, by PCR using the following primers and
conditions: Primers F: 5’-TTGAGTTGTGGTGGGTTTTA
TTTAG-3’ R: 5’-TCATCTCACTAAAAAATACCAAACA-
3’ PCR condition: (35 cycles) was denaturation at 95 °C for
30 seconds, annealing at 52 °C for 30 seconds, extension at
72 °C for 30 seconds. The PCR products (413 bp) were
digested with HinfI restriction enzyme (Fermentas), which
only recognizes and cuts repetitive elements that are ori-
ginally methylated. The digested PCR products were ana-
lyzed and quantified by capillary electrophoresis using an
Agilent Bioanalyzer. A sample of each digested PCR
product (1 μL) was loaded onto a DNA chip according
to the Agilent DNA 1000 kit protocol and analyzed by
the Bioanalyzer 2100 software. Size of unmethylated
DNA fragment was 413 bp and the methylated DNA
fragments were 247, 166, and 128 bp. LINE-1 methylation
of each sample was determined as percentage of methylated
cytosine in relation to total cytosine.Measurement of 5-methyl-2’-deoxycytidine (5MedC) content
using HPLC-ESI-MS/MS
Genomic DNA was isolated from cord blood by using the
QIAamp DNA blood Maxi kit according to the recom-
mendations of the manufacturer. DNA was enzymatically
digested to the deoxynucleoside. Briefly, 25 μg of DNA
sample was incubated with 5U of nuclease P1 at 37°C for
ten minutes. Subsequently, 10U of alkaline phosphatase
was added and the mixture was incubated at 37°C for two
hours. Following digestion, the hydrolysate was filtered
through a 0.22-mm syringe filter before analysis. A frac-
tion of 10 μl of DNA hydrolysate was subjected to analyze
5-MedC and dC by HPLC (Agilent 1200 series) equipped
with a triple quadrupole mass spectrometer (Agilent 6410
Triple Quad LC/MS).
For HPLC-MS/MS analysis, the HPLC was connected to
a Guanine adduct column (3.0 x 150 mm, ESA Inc., USA)
with the column temperature set to 25°C. A flow rate of
0.5 mL/min was used for the mobile phase of methanol
and 0.1 % formic acid. The MS/MS system was operated
via an electrospray source with a positive ion mode. The
capillary voltage was 4 kV. Nitrogen gas was used as a
nebulizer gas by setting a flow rate of 9 L/minute and a
pressure of 40 psi and a temperature at 275°C. The
product ion transition of analytes was monitored in the
MRM mode at m/z 242.1!m/z 126.3 for 5-MedC and
Table 1 Arsenic concentrations in various sources of
water from the study locations
Sources of water Arsenic concentrations (μg/L)
Study locations
Arsenic-contaminated site Control site
Well water 298.18 ± 129.60 a nd
(n = 13) 87.36 (1.11-1,475.00)b
Mountain pipe water 25.54 ± 9.02 nd
(n = 10) 6.86 (1.59-75.05)
Local tap water 24.22 ± 17.23 0.22 ± 0.11
(n = 12) 4.86 (0.53-147.60) nd (nd-1.09)
Rain water 1.01 ± 0.20 nd
(n = 23) 0.65 (0.17-2.99)
Bottled water 4.54 ± 0.43 0.20 ± 0.10
(n = 6) 4.20 (3.45-5.85) 0.06 (nd-1.20)
The values are expressed as the mean± SE (a) and median (min - max) (b).
nd : non detectable.
Table 2 Arsenic concentration in drinking and
non-drinking water samples
Study locations Arsenic concentration (μg/L)
Drinking water Non-drinking water
Arsenic-contaminated site 8.38 ± 2.49 a,* 78.05 ± 20.92*
(n =46) 0.86 (0.17-61.63)b 16.54 (1.14-518.69)
Control site 0.18 ± 0.07 0.99 ± 0.04
(n = 18) 0.04 (nd-0.98) 1.10 (nd-1.05)
The values are expressed as the mean± SE (a) and median (min - max) (b).
nd : non detectable.
* : statistically significant difference from controls at p< 0.05.
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Determination of p53 promoter methylation
p53 promoter methylation was determined according to
a previously reported method, with modification [14].
DNA was isolated from cells using Qiagen DNA isola-
tion kit. Methylation-specific restriction endonuclease di-
gestion was performed using MspI & HpaII (Promega).
The promoter region of the p53 gene contains 2 CCGG
sites beginning at bases 703 and 883 (Gen Bank accession
no: X 54156). The HpaII restriction enzyme cleaves CCGG
sequences, which are not methylated at the internal or ex-
ternal cytosine. MspI is the isoschizomer of HpaII, and
cleaves the CCGG sequence irrespective of its methylation
status. Therefore, MspI cleaves both methylated and
unmethylated cytosine while HpaII cleaves only unmethy-
lated cytosine. MspI was used as a control for HpaII diges-
tion. PCR amplification of the sequence in region (638-
978 bp) cannot be performed if one of the CCGG
sequences has been cleaved. DNA methylated at both the
CCGG sequences of the p53 promoter is resistant to HpaII
digestion and can be amplified by PCR. Genomic DNA
(300 ng) was digested with two units of HpaII or MspI at
37 °C for five hours. Enzymes were inactivated at 95 °C for
ten minutes. The HpaII and MspI-digested DNA were
amplified using p53 promoter region primers (F: 5’-
AGGGAATTCGGCACCAGGTCGGGGAGA-3’ R: 5’-
AGGATCGATGGACTCATCAAGTTCAGT-3’) for 31
cycles giving rise to a 341 bp PCR product. PCR condition
was at 94 °C for one minute, 58 °C for seventy seconds,
72 °C for three minutes. The PCR products (341 bp)
were cleaned using a Qiagen MinElute purification kit
prior to analysis with Bioanalyzer (Agilent). A sample of
each amplified DNA (1 μl) was loaded onto a DNA chip
according to the Agilent DNA 1000 kit protocol and
assayed using the Bioanalyzer 2100 software. The methyla-
tion of p53 was calculated as the ratio of HpaII: MspI
product.
Statistical analysis
The Mann-Whitney U Test was used to determine stat-
istical differences of the test parameters. The correlations
between p53 promoter methylation and arsenic accumu-
lation in nails were determined by Pearson correlation
coefficient. A p-value less than 0.05 was considered to
represent statistical significance.
Results
Arsenic concentrations in various sources of water
Arsenic concentrations in water samples from various
sources including bottled water, local supply tap water,
mountain pipe water, well water and rainwater in the con-
taminated (Ron Pibul District) and reference (control) sitesare shown in Tables 1 and 2. High levels of arsenic con-
tamination were found in well water in the contaminated
sites, where the concentrations were varied from 1-
1,475 μg/L. Varying concentrations of arsenic were also
found in other sources of water, including mountain pipe
water and local supply of tap water, but the mean levels
were approximately 12-fold lower than that in the well
water. In this site, the arsenic concentrations detected in
rainwater and bottled water were 1.01 and 4.54 μg/L, re-
spectively, which are under the World Health Organization
(WHO) guideline value (<10 μg/L) for arsenic in drinking
water. In the control site, the arsenic concentrations in
bottled water and tap water were much lower than those
from the contaminated site. Arsenic levels in drinking and
non-drinking water were approximately 46-fold (p< 0.05)
and 78-fold (p< 0.05) higher, respectively, in the samples
from arsenic-contaminated site (Table 2).Arsenic concentrations in biological samples from
newborns
Levels of arsenic accumulation in biological samples
from newborns are shown in Table 3. When compared
Table 3 Arsenic concentrations in biological samples from newborns
Groups Arsenic concentrations
Cord blood (μg/g) Toenails (μg/g) Fingernails (μg/g) Hair (μg/g)
Exposed 5.79 ± 0.5 a,* 1.52 ± 0.38*** 1.91 ± 0.38** 0.05 ± 0.01***
(n = 55) 6.27 (1.31-10.37)b 0.76 (nd-8.23) 1.45 (nd-9.08) 0.031 (nd-0.38)
Control 1.97 ± 0.64 0.12 ± 0.04 0.08 ± 0.05 0.01 ± 0.003
(n = 16) 1.25 (0.51-8.31) 0.03 (nd-0.59) 0.06 (nd-0.41) nd (nd-0.06)
The values are expressed as the mean± SE (a) and median (min - max) (b).
nd : non detectable.
*,**, *** : statistically significant difference from controls at p< 0.05, 0.01 and 0.001, respctively.
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senic accumulation in newborns from exposed mothers
living in the contaminated site was significantly greater
by approximately 3-, 12-, 24-, and 5-fold in cord blood,
toenails, fingernails and hair, respectively, thus confirm-
ing exposure in these babies.Global DNA methylation and p53 promoter methylation
in human cord blood lymphocytes as a result of arsenic
exposure in utero
Global DNA methylation and p53 promoter methylation
were determined in cord blood lymphocytes from
exposed (n = 55) and control subjects (n = 16). As shown
in Table 4, the difference in levels of global LINE-1 DNA
methylation expressed as percentage of methylated cyto-
sine in relation to total cytosine between the exposed-
and control groups, was not statistically significant.
Methylation of the p53 promotor region was slightly
higher in the arsenic-exposed group, but a significant
correlation between the level of methylation and accu-
mulation of arsenic in toenails or fingernails was
observed (p< 0.05) (Figure 1).Effects of in vitro arsenic exposure on global DNA and
p53 promotor methylation in human lymphoblasts
a) Short-term exposure to arsenic in vitro was con-
ducted by treatment of human lymphoblasts with so-
dium arsenite at concentrations ranging from 10-Table 4 Global DNA methylation and p53 promoter




(% Methylation) (Methylated cytosine: cytosine)
Exposed 83.01 ± 0.40a 1.77 ± 0.11
(n = 55) 83.47 (73.02 - 89.15)b 1.66 (1.03 - 5.03)
Control 84.44 ± 0.64 1.53 ± 0.09
(n = 16) 84.87 (79.34 - 88.33) 1.48 (1.01 - 2.19)
The values are expressed as the mean± SE (a) and median (min - max) (b).100 μM for two, four and eight hours. A significant
reduction of LINE-1 methylation was observed only
for four hours of treatment. A progressive decrease in
methylation level was observed between 10 to 50 μM,
then levelling off towards 100 μM. Global DNA methy-
lation levels in lymphoblasts-treated with arsenite for four
hours was 93.54 %, 83.68 %, 62.55 %, and 66.16 % of the
control levels at 10, 20, 50 and 100 μM, respectively. These
decreases were statistically significant at 20 μM (p< 0.05),
50 μM (p< 0.01) and 100 μM (p< 0.01). A maximum re-
duction of methylation level was observed at 50 μM
(Figure 2A).
From this observation, it was decided that the optimum
period for arsenite exposure in the subsequent experi-
ments would be four hours. Measurement of 5-MedC con-
tent in lymphoblasts exposed to different concentrations
of arsenite from 10-100 μM showed that levels were sig-
nificantly decreased at all concentrations tested (p< 0.01
at 10 μM, p< 0.001 at 50 and 100 μM). The lowest methy-
lation level was observed at concentration of 50 μM
(Figure 2B). The profile of 5MedC content in response
to arsenite exposure was consistent with the decrease in
LINE-1 methylation.
We then further explored the effect on a specific gene,
p53, at the promoter region. Using methylation-specific
restriction endonuclease digestion assay and Bioanalyzer
quantification, p53 promoter methylation was found to
increase after arsenite treatment. In arsenite-treated lym-
phoblasts (50 μM for four hours), the promoter region of
p53 was hypermethylated by approximately 1.5-fold com-
pared to the controls (p< 0.05) (Figure 2C).
b) Long-term exposure to arsenite for up to eight weeks
in the lymphoblast cells was carried out at concentrations of
0.5 and 1 μM. LINE-1 methylation in treated cells gradually
decreased starting at two weeks and over the remaining
six weeks of treatment. The level of LINE-1 methylation in
arsenite-treated cells at 1.0 μM was slightly lower than that
at 0.5 μM at all time points, except at eight weeks of treat-
ment (Figure 3A).
The level of total 5-MedC content in the treated
lymphoblast cell line was not significantly different from
the untreated levels except at six weeks of treatment,
Figure 1 Scatter plot of non parametric correlation between the level of p53 promoter methylation and arsenic accumulation in
toenails or fingernails from both exposed and unexposed newborns. R2 represent correlation coefficient and p represent p-value of the
correlation.
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treatment, both at 0.5 and 1.0 μM. The lowest levels of
5-MedC were 88 % and 91 % of the control levels at 0.5
and 1.0 μM, respectively (Figure 3B).
Two weeks of treatment with arsenite showed no effect
on p53 promoter methylation in the lymphoblast cell
line, but a dramatic increase (approximately 300 % of the
control level) was observed at four weeks (p< 0.05 and
p< 0.01 at arsenite concentrations of 0.5 and 1.0 μM, re-
spectively), with a subsequent decrease to control levels by
six weeks. Similar profiles of p53 promoter methylation
alterations in lymphoblasts with respect to time course of
treatment were observed for 0.5 and 1.0 μM of arsenite
(Figure 3C).
Discussion
Gestation period is a period of high sensitivity to chemical
exposure, since it covers the whole period of fetal develop-
ment. There is accumulating evidence that in utero expos-
ure to arsenic is associated with congenital defects and
long-term disease consequences, such as cancer. A recent
finding in whole life arsenic exposure in an animal model
indicated that in utero arsenic exposure may dictate target
site of tumor while other periods of exposure could act to
enhance the carcinogenic response [38]. Transplacental
exposure to arsenic is thought to lead to the gestational
disruption of epigenetic gene imprinting during this sus-
ceptible period of fetal development [25]. Aberrant DNA
methylation and gene expression in livers were observed
in newborn mice transplacentally exposed to inorganic
arsenic [39].
In human, in utero or early childhood exposure to ar-
senic in drinking water was associated with increased
mortality in young adults in Chile from both malignant
and non-malignant lung disease [18,19]. Our previousreport demonstrated for the first time that arsenic expos-
ure in utero resulted in gene expression changes in the
newborns of mothers living in arsenic contaminated
areas during pregnancy [28]. The present study further
investigates other effects of such exposure such as those
on DNA methylation, which plays a key role in the con-
trol of gene expression.
Globally, the most important source of arsenic expos-
ure in humans is drinking water [40]. This study clearly
showed that arsenic contamination in various sources of
consumable water was much higher in the contaminated
site, with arsenic concentrations in drinking water being
approximately 46-fold higher than those from the con-
trol site (8.38 versus 0.18 μg/L, p< 0.05). Although the
level of arsenic detectable in drinking water was below
the established WHO standard of 10 μg/L, arsenic expos-
ure was found to be significantly higher in the newborns
of mothers living in this contaminated site. Arsenic expos-
ure in these newborns was assessed using biomarkers of
exposure, including arsenic concentrations in biological
samples, i.e cord blood, nails and hair. Detection of arsenic
in these biological samples is indicative of systemic absorp-
tion after arsenic exposure [41]. When compared to the
control group, exposed newborns had significantly higher
concentrations of arsenic in cord blood (3-fold), nails
(10- and 20-fold in toenails and fingernails, respectively)
and hair (5-fold). Based on the fold level of increase, ar-
senic accumulation in hair and nails could be considered
good biomarkers of arsenic exposure. Absorbed arsenic
accumulates in hair and nails, and it is thought that this
involves the binding of Asiii to the sulhydryl groups in
keratin. Due to the slow growth of hair and nails, arsenic
accumulation is an indication of past arsenic exposure
and thus can be used as biomarkers for long-term arsenic






p53 promoter methylation 
Figure 2 Lymphoblasts were treated with NaAsO2 at 0, 10, 20, 50 and 100 μM for two, four or eight hours. Levels of DNA methylation
expressed as % of controls were illustrated as a dose-response and time-course study on global LINE-1 methylation determined by COBRA and
quantified by capillary gel electrophoresis using a Bioanalyzer (A), dose-response of arsenite treatment on total 5-MedC content determined by
HPLC-MS/MS in lymphoblasts at four hours of treatment (B) and p53 promoter methylation in lymphoblasts treated with arsenite at 50 μM for
four hours (C). Each point represents the mean± SE from three independent experiments. *,** and *** represent statistically significant difference
from control at p< 0.05, 0.01 and p< 0.001, respectively.




C : p53 promoter methylation
5-MedC content 
LINE-1 methylation 
Figure 3 Lymphoblasts were treated with NaAsO2 (0.0, 0.5 and 1.0 μM) for two up to eight weeks. The experiment was performed twice.
Dose-response and time-course of arsenite treatment on levels of DNA methylation expressed as % of controls was determined as Global LINE-1
methylation determined by COBRA, quantified by capillary gel electrophoresis using a Bioanalyzer (A), total 5-MedC content determined by HPLC-
MS/MS (B) and p53 promoter methylation (C). Each point represents the mean± SE from three independent experiments. * and ** represent
statistically significant difference from control at p< 0.05 and p< 0.01, respectively.
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levels of accumulation in nails [42] and hair [43]. Analysis
of arsenic in blood is suitable for recent and high level of
exposure, but it may not be a reliable biomarker of arsenic
exposure because it is cleared rapidly, particularly for low
levels of inorganic arsenic [3,44].
Growing evidence indicates that arsenic carcinogenesis
involves, either directly or indirectly, altered epigenetic
regulation in gene expression changes induced by arsenic
exposure [45]. Epigenetic changes in methylation patterns
are increasingly implicated in cancer development [10].
The mechanism underlying the epigenetic changes in
DNA methylation mediated by arsenic has been proposed
to involve arsenic modulating the activity of DNA methyl-
transferase (DNMT), which catalyzes the transfer of a
methyl group from S-adenosylmethionine (SAM) on to
the 5’-position of cytosine at a CpG dinucleotide to pro-
duce 5-methylcytosine. It has been reported that arsenic
inhibits DNMT activity and expression of DNMT1,
DNMT3A, and DNMT3B [46-48] as well as depletes
SAM, resulting in genome-wide hypomethylation [7,48].
In addition, it has been reported that arsenic mediates
the disruption of normal epigenetic control at specific
loci, such as the promoter regions of the tumor suppres-
sor genes p53 and p16, which may result in aberrant
gene expression and cancer [39,49]. Generally, global
hypomethylation, as well as hypermethylation, have
been associated with reduced chromosomal stability
and altered genome function. Gene promoter hyper-
methylation is associated with decreased gene expres-
sion [50].
In this study, impacts of arsenic exposure on DNA
methylation were investigated, focusing on global and
gene-specific methylation. Methylation of repetitive
elements of LINE-1 represents approximately 17 % of
the human genome [51]. Because of high level of
methylation in normal tissue and close correlation with
genomic DNA methylation content, LINE-1 methyla-
tion status has been used as a surrogate marker for es-
timating the genome-wide methylation level [34].
The present study showed that prenatal arsenic expos-
ure did not cause a significant change in global LINE-1
methylation in newborns from the arsenic-exposed
mothers, compared to those from the unexposed
mothers living in the control site. This observation is
consistent with those from animal studies which in utero
arsenic exposure in mice was not associated with any
changes in global DNA methylation [23,39].
To achieve a better understanding of the epigenetic
effects of arsenic exposure, DNA methylation was fur-
ther investigated in vitro, through short-term and long-
term exposure using a human lymphoblast cell line. The
low concentrations of arsenic used in the long-termin vitro study are non-cytotoxic, corresponding to 37
and 74 ppb, which are level that can be found in con-
taminated environment, since 0.67 μM of arsenite is
equivalent to 50 ppb [52]. The short-term in vitro study
used higher concentrations of arsenic, including 10, 20,
50 and 100 μM, equivalent to 750, 1500, 3700 and
7400 ppb, respectively, to demonstrate more observable
effects of arsenic exposure and to better characterize of its
mechanism of action. These high concentrations of arsenic
in water have been found in some areas, such as Taiwan
(above 600 μg/L) [53] and up to 7500 μg/L in Argentina
[54].
Apart from LINE-1 methylation, total 5-MedC content
was also determined as another indicator of genome-
wide methylation. Measurement of 5-MedC content using
HPLC-MS/MS has been shown to be a rapid, sensitive
and specific technique for detection of global methyla-
tion in the genome [55,56]. Following short-term
in vitro arsenite treatment, the dose-response and time-
course study clearly demonstrated a significant global
hypomethylation, observed as a reduction in LINE-1
methylation and total 5-MedC content in lymphoblasts
exposed to arsenite (10-100 μM) for four hours, but not
at two hours or eight hours. The reduction of LINE-1
methylation observed at four hours was found to correl-
ate significantly with the highest levels of DNA strand
breaks in arsenite-treated lymphoblasts (data not
shown), suggesting a possible link between DNA dam-
age (which, in the case of arsenic, is known to be due to
oxidative stress) and LINE-1 methylation. This observa-
tion was consistent with the previous finding that high
levels of oxidative DNA damage may induce global
DNA hypomethylation as a result of oxidative damage of
methylated cytosine residues, which is a template recog-
nition site for DNMT [57]. In the long-term study, glo-
bal DNA hypomethylation was also observed following
treatment with low concentrations of arsenite at 0.5 and
1.0 μM. These results suggested that global DNA hypo-
methylation can be mediated by arsenic exposure at low
concentrations, but the extent of methylation is
dependent on the concentration and duration of expos-
ure. Global DNA hypomethylation has been proposed to
contribute to carcinogenesis via activation of oncogenes
and inactivation of tumor suppressor genes, as well as
chromosomal aberrations and increased mutation rates
[58-60]. As a consequence, arsenic exposure may lead to
diseases and cancer outcomes through genome-wide
hypomethylation.
Regarding gene-specific methylation, methylation at
the promoter region of p53 was investigated since p53 is
a key factor in the damage-signaling pathway. The tumor
suppressor p53 gene plays a significant role in a variety
of cellular functions, including cellular stress, regulation
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dence indicates that arsenic exposure predisposes cells to
malignant transformation via alterations of p53 expres-
sion and function [61], p53 mutation [62], as well as
alterations of p53 methylation [14].
In this study, global DNA methylation levels were
not significantly changed, while p53 promoter methy-
lation was slightly increased in exposed newborns.
We observed high variation in arsenic exposure levels
within the exposed group, which led to a broad range
of p53 promoter methylation levels. However, the sig-
nificant correlation between p53 promoter methylation
and accumulation of arsenic in nail samples indicated
that arsenic exposure increased p53 promoter methy-
lation. These results appear to be in line with obser-
vations in the animal study that arsenic exposure in
utero may affect specific DNA methylation changes at
targeted sites rather than global hypomethylation [7].
A slight increase in p53 promoter methylation as well
as unchanged global methylation in these arsenic-
exposed newborns was possibly due to a relatively low
level of arsenic exposure in our study. Level of arsenic
contamination in the environment and particularly in
drinking water in this study site (<10 μg/L) was lower
than in other arsenic-contaminated sites. Arsenic
levels in drinking water were greater than 400 μg/L in
West Bengal, India [63] and approximately 50 μg/L in
Bangladesh [64].
Short-term in vitro arsenite treatment clearly resulted
in hypermethylation of p53 at the promoter region in
treated-lymphoblasts at 50 μM. This result is in agree-
ment with previous studies in which hypermethylation of
p53 was observed in arsenite-treated A549 cells [14], as
well as in arsenic exposed patients with skin cancer who
were chronically exposed to high arsenic-contaminated
drinking water at levels ranging between 300-1000 μg/L
[15]. Hypermethylation of p53 promoter region may be
due to overexpression of DNMT1, which was shown to
be overexpressed and correlated with hypermethylation
of CpG island of other genes, i.e hMLH1 and THBS1
[65]. This may suggest the possible involvement of
increased expression of DNMT1 in hypermethylation
of specific-genes. However, long-term in vitro arsenite
treatment showed a transient hypermethylation of p53
in lymphoblasts at six weeks of treatment, then
decreased. This may be due to the fact that prolonged
arsenic exposure may cause depletion of the SAM
pool through overconsumption of methyl groups by
DNMT, resulting in an inability to maintain methy-
lated cytosine in DNA. In addition, evidence from the
in vitro study showed that DNA methylation status in
specific genes may change rapidly in response to envir-
onmental stressors [66].Conclusions
Our results demonstrate that in humans, in utero expos-
ure to arsenic in the environment affects DNA methyla-
tion, particularly at the promoter region of p53 causing
hypermethylation although alterations in global DNA
methylation were not detectable. A significant correlation
between p53 promoter hypermethylation and arsenic
accumulation in nails was observed. These findings
confirmed by in vitro exposure studies in human lym-
phoblasts that arsenic causes hypermethylation of p53
promoter region as well as global hypomethylation. These
results contribute possible mechanistic evidence for the
previously reported epidemiological observation that in
utero exposure to arsenic in drinking water was associated
with an increased mortality in young adults in Chile from
malignant and non-malignant lung diseases.
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